Cargando…

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives

Systemic immunoglobulin light chain (AL) amyloidosis is a disorder characterized by the production of clonal serum free light chains that misfold, aggregate, and deposit in vital organs. Treatment of this disease is typically targeted at the abnormal plasma cell clone in the bone marrow which is the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarosiek, Shayna, Sanchorawala, Vaishali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815750/ https://www.ncbi.nlm.nih.gov/pubmed/31695543 http://dx.doi.org/10.2147/JBM.S183857

Ejemplares similares

Detection of minimal residual disease by next generation sequencing in AL amyloidosis
por: Sarosiek, Shayna, et al.
Publicado: (2021)

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis
por: Hughes, David, et al.
Publicado: (2020)

Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis
por: Sarosiek, Shayna, et al.
Publicado: (2020)

Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following Stem Cell Transplantation
por: Lohrmann, Graham, et al.
Publicado: (2020)

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics
por: Fraser, Cameron S., et al.
Publicado: (2022)

Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities
por: Staron, Andrew, et al.
Publicado: (2020)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes
por: Gustine, Joshua N., et al.
Publicado: (2022)

Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis
por: Sanchorawala, Vaishali
Publicado: (2022)

A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis
por: Dispenzieri, Angela, et al.
Publicado: (2021)

Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis
por: Ravichandran, Sriram, et al.
Publicado: (2022)

Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans
por: Staron, Andrew, et al.
Publicado: (2022)

Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis
por: Mendelson, Lisa, et al.
Publicado: (2022)

Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples
por: White, Michelle K, et al.
Publicado: (2017)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Light Chain (AL) Amyloidosis: The Journey to Diagnosis
por: McCausland, Kristen L., et al.
Publicado: (2017)

First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma
por: Oliver-Caldes, Aina, et al.
Publicado: (2021)

Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report
por: Li, Xian, et al.
Publicado: (2022)

Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis
por: Gustine, Joshua N., et al.
Publicado: (2023)

Light chain (AL) amyloidosis: update on diagnosis and management
por: Rosenzweig, Michael, et al.
Publicado: (2011)

Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study
por: Staron, Andrew, et al.
Publicado: (2021)

Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group
por: Rizio, Avery A, et al.
Publicado: (2023)

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma
por: Frontzek, Fabian, et al.
Publicado: (2022)

Racial disparities in patients diagnosed with light chain (AL) amyloidosis
por: D’Souza, Anita, et al.
Publicado: (2021)

Light Chain (AL) Cardiac Amyloidosis: A Diagnostic Dilemma
por: Abdelazeem, Basel, et al.
Publicado: (2021)

Differences in Immunoglobulin Light Chain Species Found in Urinary Exosomes in Light Chain Amyloidosis (AL)
por: Ramirez-Alvarado, Marina, et al.
Publicado: (2012)

Evaluating the Amyloidosis Speakers Bureau: the influence of amyloidosis patients’ narratives on medical students’ knowledge, attitudes, and behavioral intent
por: Adebayo, Adebanke L., et al.
Publicado: (2023)

Lingual liability: macroglossia and dyspnoea as the harbinger of systemic AL (light-chain) cardiac amyloidosis
por: Williams, Michael Uncle, et al.
Publicado: (2018)

Autopsy findings in a patient with primary systemic AL (kappa light chain) amyloidosis
por: Ledesma, Felipe Lourenço, et al.
Publicado: (2021)

Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics
por: Rognoni, Paola, et al.
Publicado: (2021)

Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis
por: Morgan, Gareth J., et al.
Publicado: (2021)

Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study
por: Lebel, Eyal, et al.
Publicado: (2023)

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
por: Gertz, Morie A., et al.
Publicado: (2023)

A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time
por: Sanchorawala, Vaishali, et al.
Publicado: (2017)

PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Complete variable domain sequences of monoclonal antibody light chains identified from untargeted RNA sequencing data
por: Nau, Allison, et al.
Publicado: (2023)

T1 mapping and survival in systemic light-chain amyloidosis
por: Banypersad, Sanjay M., et al.
Publicado: (2015)

Systemic Light Chain Amyloidosis Mimicking Rheumatic Disorders
por: Rao, Rohit R., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0q65fg1u4gevcvcp0e85d8ldeo